OncoMatch/Clinical Trials/NCT06523621
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
Is NCT06523621 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nivolumab for multiple myeloma.
Treatment: Nivolumab — This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: CAR-T cell therapy (idecabtagene vicleucel) — per FDA approved US prescribing information
Previous treatment with idecabtagene vicleucel according to the FDA approved US prescribing information with a response of CR/sCR, VGPR or PR by IMWG 2016 criteria
Cannot have received: autologous stem cell transplant
Exception: allowed if >12 weeks before C1D1
Autologous stem cell transplant within 12 weeks of C1D1
Cannot have received: allogeneic stem cell transplant
Allogeneic stem cell transplant
Cannot have received: solid organ transplant
Solid organ transplant
Lab requirements
Blood counts
Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 28 days prior to enrollment.
Kidney function
Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 28 days prior to enrollment.
Liver function
Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 28 days prior to enrollment.
Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 28 days prior to enrollment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Levine Cancer Institute · Charlotte, North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Winston-Salem, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify